Amneal ‘Very Excited’ About Biosimilars Future, Looks To Expand Portfolio In 2024
Complex Generics Also Remain Key R&D Focus Area, Particularly Inhalators And Injectables
Amneal continues to see a bright future in the biosimilars business as it looks for new portfolio additions, and gets ready for several complex product launches, some even yet to be disclosed, this year.
